Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.44 |
| ▸ | FNTA | P49354 | 7/20 | 0.43 |
| ▸ | FNTB | P49356 | 5/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.43 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21571159 | 0.84 | BTN3A1 (0.76) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL4631198 | 0.84 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL29177519 | 0.82 | CYP3A4 (0.64) | CYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL26559 | 0.82 | CYP3A4 (0.64) | CYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL15389152 | 0.82 | CYP3A4 (0.64) | CYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL21764811 | 0.81 | CYP3A4 (0.44) | BTN3A1CYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL150664 | 0.80 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR1LPAR2 | |
| Ammonia Solution, Strong SCHEMBL5519376 | 0.80 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR1LPAR2 | |
| Methane SCHEMBL11359992 | 0.80 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL11677508 | 0.80 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023250347-A1 | METHODS TO REDUCE CONTAMINATION, BIOFILM, AND FOULING FROM WATER SYSTEMS AND SURFACES | AEQUOR, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | AEQUOR, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | AEQUOR, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| WO-2022081594-A1 | ANTIMICROBIAL COMBINATION THERAPEUTICS | AEQUOR, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3984540-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | Aequor, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20200060280-A1 | Antimicrobial Compounds and Methods of Use | AEQUOR, INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200060280-A1 | Antimicrobial Compounds and Methods of Use | DDT, PFAS, DSTN | BTN3A1 949/4885CYP3A4 2361/4885LPAR3 3397/4885 |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | DDT, AS3MT, GPX4 | BTN3A1 554/4885CYP3A4 1048/4885LPAR3 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.